Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 10/20 | 0.60 |
| ▸ | REN | P00797 | 7/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.50 |
| ▸ | PLK2 | Q9NYY3 | 3/20 | 0.50 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.46 |
| ▸ | CALCR | P30988 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13470572 | 1.00 | PLK1 (0.60) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL15729140 | 1.00 | PLK1 (0.60) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL15729376 | 0.96 | PLK1 (0.61) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL15729407 | 0.95 | PLK1 (0.55) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL17518878 | 0.95 | PLK1 (0.55) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL17518828 | 0.95 | PLK1 (0.55) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL16118966 | 0.94 | PLK1 (0.58) | PLK1RENPLK3PLK2RAMP3 | |
| SCHEMBL15729189 | 0.93 | PLK1 (0.69) | PLK1RENPLK3PLK2 | |
| SCHEMBL20920239 | 0.93 | PLK1 (0.62) | PLK1RENPLK3PLK2CTSD | |
| SCHEMBL15729193 | 0.92 | PLK1 (0.64) | PLK1RENPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039872-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039872-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | PLK1, PHKG1, ACP1 | PLK1 1/4885REN 4454/4885PLK3 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.